AIM-quoted Ondine Biomedical (LSE:OBI) Inc. said on 28 October 2026 that additional safety and patient-reported tolerability results from its Phase 3 LANTERN trial had been presented at IDWeek 2026, as Poster P-1520. The poster was co-presented with the company's partner, HCA Healthcare's institute (HRI).
4basebio PLC operates in an environment where synthetic DNA manufacturing and commercial adoption. Its investment case depends not only on the size of its addressable market but also on management’s ability to translate activity into sustainable earnings and cash. Investors typically distinguish between a …
Abingdon Health Plc operates in an environment where diagnostics manufacturing and customer contracts. Its investment case depends not only on the size of its addressable market but also on management’s ability to translate activity into sustainable earnings and cash. Investors typically distinguish between a …
Haleon PLC operates in an environment where consumer health brands, volume growth and margins. Its investment case depends not only on the size of its addressable market but also on management’s ability to translate activity into sustainable earnings and cash. Investors typically distinguish between …
Recent company developments, sector changes and expectations can influence the market even without a single decisive announcement. The most useful distinction is between information already reported and outcomes that remain contingent on management execution. For Bioventix Plc, the specific focus is royalty demand, assay …
Recent company developments, sector changes and expectations can influence the market even without a single decisive announcement. The most useful distinction is between information already reported and outcomes that remain contingent on management execution. For CRISM Therapeutics Corporation, the specific focus is clinical programme …
Recent company developments, sector changes and expectations can influence the market even without a single decisive announcement. The most useful distinction is between information already reported and outcomes that remain contingent on management execution. For HemoGenyx Pharmaceuticals Plc, the specific focus is clinical development, …
Recent company developments, sector changes and expectations can influence the market even without a single decisive announcement. The most useful distinction is between information already reported and outcomes that remain contingent on management execution. For Inspiration Healthcare Group PLC, the specific focus is hospital …
Sareum Holdings PLC (LSE:SAR), which describes itself as a clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer, published the result of its retail offer on 28 October 2026. The announcement follows the company's statements of 26 October 2026, including one …
Investors are assessing how company-specific execution could influence earnings quality and future valuation.